ClinicalImpact™ RET-Altered or RET-Driven NSCLC and Thyroid Cancer: Expert Guidance for Improving Outcomes

Listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, including testing for RET fusions, using new selective RET inhibitors in these patients, and the importance of interdisciplinary communication.

Dara L. Aisner, MD, PhD Joshua Bauml, MD Released: September 17, 2020

Download this short summary slideset of key takeaways from a podcast on RET fusion–positive NSCLC.

Dara L. Aisner, MD, PhD Joshua Bauml, MD Released: September 17, 2020

Using a recent patient case from my practice, I describe how I am incorporating new selective RET inhibitors such as selpercatinib into managing patients with RET fusion–positive NSCLC.

Karen L. Reckamp, MD, MS Released: September 2, 2020